论文部分内容阅读
目的:分析高血压患者接受缬沙坦联合氢氯噻嗪联合治疗后的血压达标率。方法:选择门诊轻中度高血压患者220例,均采用缬沙坦联合氢氯噻嗪治疗6周。初始剂量为缬沙坦80mg,氢氯噻嗪片12.5mg,治疗1-2周;如未达标(收缩压<140mmHg,舒张压<90mmHg,1mmHg=0.133KPa),则增加缬沙坦至160mg,继续应用2周;4周后仍不达标者,将氢氯噻嗪增加至25mg,口服,治疗6周试验结束。结果:对入选的220例轻中度高血压患者进行为期6周的随访,对其中200例患者进行符合方案人群分析:①治疗1周时,收缩压/舒张压与治疗前比较,分别降低14.39/8.85mmHg,P<0.01;治疗6周时,收缩压/舒张压分别降低23.97/16.21mmHg,P<0.001;②治疗2周时,血压达标的患者为120例,占60%,4周血压达标的患者为150例,占75%,6周血压达标的患者为175例,占87.5%;③在治疗的6周中,服用缬沙坦80mg、氢氯噻嗪12.5mg的患者有120例;服用缬沙坦160mg、氢氯噻嗪12.5mg的患者有80例;服用缬沙坦160mg、氢氯噻嗪25mg的患者有20例;④对入组的220例高血压患者进行意向治疗人群分析,其中,有212例无任何不良反应,占总例数的96%。结论:缬沙坦与氢氯噻嗪联合治疗轻中度高血压病,达标率高,不良反应少。
OBJECTIVE: To analyze the blood pressure compliance rate of hypertensive patients receiving valsartan and hydrochlorothiazide combination therapy. Methods: 220 outpatients with mild to moderate hypertension were selected and treated with valsartan combined with hydrochlorothiazide for 6 weeks. The initial dose of valsartan 80mg, hydrochlorothiazide tablets 12.5mg, for 1-2 weeks; if not up to (systolic blood pressure <140mmHg, diastolic blood pressure <90mmHg, 1mmHg = 0.133KPa), increase valsartan to 160mg, continue to apply 2 Week; 4 weeks after the standard is still not reached, the hydrochlorothiazide increased to 25mg, oral, 6 weeks of treatment end of the trial. Results: A total of 220 selected patients with mild to moderate hypertension were followed up for 6 weeks. 200 of them were enrolled in the program. The systolic blood pressure / diastolic blood pressure decreased by 14.39 / 8.85mmHg, P <0.01; treatment of 6 weeks, systolic blood pressure / diastolic blood pressure decreased 23.97 / 16.21mmHg, P <0.001; 2 weeks of treatment, blood pressure reached the standard of 120 patients, accounting for 60% 175 patients (87.5%) met the standard of 6-week blood pressure; (3) 120 patients took valsartan 80 mg and hydrochlorothiazide 12.5 mg in the 6 weeks of treatment; Sartan 160mg, hydrochlorothiazide 12.5mg in patients with 80 cases; taking valsartan 160mg, hydrochlorothiazide 25mg in patients with 20 cases; ④ The inclusion of 220 cases of hypertensive patients intention-to-treat analysis of the population, of which 212 cases without any Adverse reactions, accounting for 96% of the total number of cases. Conclusion: Valsartan and hydrochlorothiazide combined treatment of mild to moderate hypertension, high compliance rate, fewer adverse reactions.